These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25047139)

  • 1. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.
    Yang J; Pradhan RS; Rosen LS; Graham AM; Holen KD; Xiong H
    J Clin Pharm Ther; 2014 Dec; 39(6):680-4. PubMed ID: 25047139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
    Salem AH; Yang J; Graham A; Patnaik A; Holen K; Pradhan R; Xiong H
    Anticancer Res; 2014 Apr; 34(4):2001-6. PubMed ID: 24692738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
    Wilson WH; O'Connor OA; Czuczman MS; LaCasce AS; Gerecitano JF; Leonard JP; Tulpule A; Dunleavy K; Xiong H; Chiu YL; Cui Y; Busman T; Elmore SW; Rosenberg SH; Krivoshik AP; Enschede SH; Humerickhouse RA
    Lancet Oncol; 2010 Dec; 11(12):1149-59. PubMed ID: 21094089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
    Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
    Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
    Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
    Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
    Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
    Abbas R; Boni J; Sonnichsen D
    Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.
    Choo EF; Boggs J; Zhu C; Lubach JW; Catron ND; Jenkins G; Souers AJ; Voorman R
    Drug Metab Dispos; 2014 Feb; 42(2):207-12. PubMed ID: 24212376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
    Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
    J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
    Li T; Li X; Jiang X; Wang C; Sun F; Liu Y; Lin P; Shi P; Fu Y; Gao X; Zhang Y; Cao Y
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):409-415. PubMed ID: 36107220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.